NIAID to Conduct Observational Clinical Study to Identify Genetic Factors in 500 Patients with Rare Immune Diseases, Including APDS and CTLA4 Deficiency
NIAID's Large-Scale Observational Study to Identify Primary Immunodeficiency Disorders
The clinical trial (NCT02257892), led by the National Institute of Allergy and Infectious Diseases (NIAID), is a large-scale observational study aimed at elucidating the underlying causes of genetic disorders of the immune system. The study is recruiting a large cohort of up to 500 patients with rare immune diseases, including Activated PI3K delta syndrome (APDS), CTLA-4 deficiency, STAT3 Gain-of-Function, and XMEN disease, as well as their family members. Launched in 2014 and scheduled to be completed in August 2026, the study prioritizes systematically tracking the natural history of rare immune deficiency diseases to reveal genetic mechanisms.
Laying the Foundation for Precision Medicine through Next-Generation Sequencing
The researchers collect various biological samples, including blood, saliva, and skin biopsies, from patients and their relatives to perform detailed genetic analyses. In particular, they plan to utilize whole exome sequencing and whole genome sequencing to intensively identify genetic variations involved in the activation or apoptosis of immune cells. The construction of such a vast genomic dataset will serve as a strong foundation for precision medicine and the development of customized therapies tailored to the individual genetic characteristics of each patient. This is a key process in identifying biomarkers that target the underlying genetic causes, rather than simply alleviating temporary symptoms.
Synergy with Commercialized Therapies and Addressing Unmet Needs
The field of rare immune deficiency diseases has been challenging for new drug development due to the small number of patients, making it difficult to establish disease models and lacking sufficient clinical data. However, with Pharming Group's APDS treatment, Joenja (leniolisib), receiving FDA approval and marking a commercial breakthrough, and Bristol Myers Squibb's Orencia (abatacept) being used to treat CTLA4 deficiency, the era of targeted therapies has arrived. At this point, if NIAID's natural history study data accumulates, it will provide strong scientific evidence to improve the efficacy of existing targeted therapies or develop new drugs with novel mechanisms.
Investment Appeal and Long-Term Growth Potential of the Rare Immune Disease Market
The global APDS treatment market is estimated at approximately $238 million in 2025 and is projected to grow at an annual rate of 8.4% to reach approximately $492 million in 2034. In addition, the overall primary immunodeficiency (PID) treatment market is also expected to exceed $12.8 billion by 2033, making it a high-growth area. The results of this NIAID study are likely to provide global pharmaceutical companies and venture capital firms with investment opportunities to discover promising early-stage pipelines and secure exclusive patent rights.
This observational study accumulates genomic data from 500 patients with APDS and CTLA4 deficiency, which is valuable as it will provide key biomarkers to accelerate the development of targeted new drugs in the future. With Pharming Group's APDS treatment, Joenja, demonstrating commercial viability with FDA approval, the APDS market, estimated at $238 million in 2025, is expected to grow to $492 million in 2034 with an annual growth rate of 8.4%. In addition, the demand for new targeted therapies is rapidly increasing in the CTLA4 deficiency field, where existing immunomodulatory agents such as Bristol Myers Squibb's Orencia are used off-label, and early entry of follow-up pipelines is expected. Venture capital and the pharmaceutical industry are expected to strengthen their efforts to secure exclusive early-stage pipelines based on the new genetic variation data to be discovered through this long-term natural history study. As a result, this study is expected to serve as a long-term catalyst for establishing a scientific basis for the development of treatments for primary immunodeficiency (PID), which has high unmet needs, and increasing the clinical success rate of new drug candidates.
Source: ClinicalTrials.gov (api_ct)